We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Fully-Automated Chemiluminescence Analyzer Enables Fast, Convenient Testing in Clinical and Emergency Settings

By LabMedica International staff writers
Posted on 15 May 2023

In recent times, there has been a surge in the need for fast and convenient testing in clinical and emergency scenarios. More...

Furthermore, the constant rise in the standards for test performance and result accuracy is driving advancements in in-vitro diagnostic (IVD) test platforms. Now, a strategic partnership has now further expanded the range of diagnostic solutions available for laboratories in China by offering a fully automated chemiluminescence immunoassay (CLIA) analyzer along with compatible assay kits to serve the region's patient community.

Roche Diagnostics China (Basel, Switzerland) is the exclusive agent in mainland China of RealMind Biotech’s (Nanjing, China) MCL60 CLIA analyzer, along with its matching chemiluminescence assay kits (including cardiac biomarkers, inflammatory biomarkers, sexual hormones, thyroid function, stomach function, etc.). The MCL60 bench-top CLIA system employs direct CLIA with acridinium ester (AE) label and is compatible with various sample types, such as capillary blood, whole blood, serum, and plasma. The MCL60 is fully automated with a throughput of up to 144 tests/hour, and the first result is available in 13 minutes. It fulfills the clinical requirements for flexible, convenient, precise, and efficient testing, and is applicable in a wide range of departments including pediatrics, obstetrics, emergency, and ICUs.

Traditional automatic chemiluminescence analyzers are typically larger in size, come with numerous accessories, and are costly, hence they are typically situated only in central or emergency laboratories. The MCL60 integrates the benefits of CLIA technology into a more compact platform, achieving high-accuracy, high-throughput, and miniaturized automatic CLIA testing. It requires minimal lab space and can execute over 70 highly sensitive assays including cardiac, inflammatory, children growth hormones, gastric function, cytokines, glycometabolism, preeclampsia, etc.

Related Links:
RealMind Biotech 
Roche Diagnostics China 


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Plasmodium Test
Plasmodium DNA Real Time PCR Kit
New
Respiratory Syncytial Virus Test
OSOM® RSV Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Switching to an experimental drug after liquid biopsy detection of breast cancer recurrence can improve outcomes (Photo courtesy of Shutterstock)

Treatment Switching Guided by Liquid Biopsy Blood Tests Improves Outcomes for Breast Cancer Patients

Standard treatment for patients with advanced estrogen receptor (ER)-positive, HER2-negative breast cancer, a subtype driven by estrogen receptors that fuel tumor growth, often involves aromatase inhibitors,... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.